Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: old-fashioned (3), old (260), square (21)

Abiraterone-Prednisolone ver1.1

Description: Chemotherapy Protocol PROSTATE ABIRATERONE-PREDNISOLONE Funding may be required for specific indications Regimen Prostate-Abiraterone-Prednisolone Indication Second line treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Abiraterone-Prednisolone-ver1.1.pdf

Afatinib Ver 1

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Regimen AFATINIB NSCLC - Afatinib Indication Treatment of locally advanced or metastatic non-small
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AfatinibVer1.pdf

Everolimus v1.1

Description: Chemotherapy Protocol RENAL CELL EVEROLIMUS This protocol may require funding Regimen Renal Cell - Everolimus Indication Advanced renal cell carcinoma that has
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Everolimus-v1.1.pdf

Vinblastine Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA VINBLASTINE Regimen Lymphoma – Vinblastine Indication Non-Hodgkin’s Lymphoma Hodgkin’s Lymphoma Toxicity Drug Vinblastine Adverse Effect Peripheral
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Vinblastine-Ver-1.1.pdf

Rituximab (weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (weekly) Regimen Lymphoma – Rituximab (weekly) Indication CD20 positive indolent non Hodgkin’s lymphoma. Toxicity Drug Rituxumab Adverse
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-weekly.pdf

Rituximab (3 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (3 Weekly) Regimen Lymphoma – Rituximab (3 weekly) Indication Non Hodgkin’s Lymphoma in combination with chemotherapy Toxicity
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-3-weekly.pdf

Prednisolone – Vincristine (Pre phase) Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA PREDNISOLONE - VINCRISTINE (Pre phase) Regimen Lymphoma – Prednisolone-Vincristine (Pre phase) Indication Non-Hodgkin’s Lymphoma Toxicity Drug Prednisolone
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Prednisolone-–-Vincristine-Pre-phase-Ver-1.1.pdf

Ibrutinib (WM) (420mg)

Description: Chemotherapy Protocol Waldenström's Macroglobulinaemia (WM) Regimen Ibrutinib • WM – Ibrutinib (420mg) Indication • The treatment of adult patients with Waldenström's Macroglobulinaemia (WM) who
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Ibrutinib-WM-420mg.pdf

Chlorambucil Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CHLORAMBUCIL There are multiple versions of this protocol in use. Please ensure you have the correct protocol for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Chlorambucil-Ver-1.1.pdf

Trabectedin v1

Description: Chemotherapy Protocol SARCOMA Regimen TRABECTEDIN Sarcoma-Trabectedin Indication Trabectedin is recommended as a possible treatment for people with advanced soft tissue
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/Trabectedin-v1.pdf

591 to 600 of 1000

Previous … 58 59 60 61 62 … Next